Table 2 Prognostic factors for disease-specific survival of 238 patients
Variables | n (%) | Univariate | Multivariable | ||||
|---|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | Pvalue | Hazard ratio | 95% CI | Pvalue | ||
Age (≥65) | 138 (58%) | 1.04 | 0.67 – 1.61 | 0.843 |  |  |  |
Gender (female) | 59 (25%) | 1.29 | 0.79 – 2.05 | 0.301 |  |  |  |
Subtype (distal nondiffuse) | 136 (57%) | 0.43 | 0.28 – 0.67 | <0.001 | 0.64 | 0.40 – 1.01 | 0.056 |
Carcinoembryonic antigen (>5 ng/ml) | 47 (20%) | 1.48 | 0.86 – 2.42 | 0.149 |  |  |  |
Carbohydrate antigen 19-9 (>37 IU/ml) | 44 (18%) | 1.98 | 1.17 – 3.20 | 0.012 | 1.23 | 0.71 – 2.06 | 0.445 |
Tumor size (≥50 mm) | 129 (54%) | 2.86 | 1.78 – 4.80 | <0.001 | 1.40 | 0.83 – 2.42 | 0.211 |
Tumor depth (pT4, UICC) | 110 (46%) | 4.17 | 2.61 – 6.88 | <0.001 | 1.38 | 0.78 – 2.50 | 0.273 |
Tumor differentiation (undifferentiated) | 139 (58%) | 2.03 | 1.28 – 3.32 | 0.002 | 1.45 | 0.83 – 2.60 | 0.197 |
Lymphatic involvement | 203 (85%) | 6.31 | 2.36 – 25.8 | <0.001 | 1.45 | 0.45 – 6.50 | 0.559 |
Vessel invasion | 134 (56%) | 2.65 | 1.66 – 4.37 | <0.001 | 1.75 | 1.07 – 2.97 | 0.026* |
Invasive growth | 83 (35%) | 3.03 | 1.97 – 4.70 | <0.001 | 1.19 | 0.70 – 2.05 | 0.520 |
Lymph node metastasis | 149 (63%) | 7.02 | 3.70 – 15.1 | <0.001 | 1.38 | 0.56 – 3.81 | 0.503 |
Peritoneal lavage cytology (positive) | 50 (21%) | 4.33 | 2.76 – 6.74 | <0.001 | 1.87 | 1.14 – 3.06 | 0.014* |
UICC stage (III-IV) | 140 (59%) | 9.68 | 4.97 – 21.8 | <0.001 | 2.63 | 0.94 – 7.83 | 0.065 |
Decreased PDSS2 mRNA in GCs | 76 (32%) | 2.18 | 1.40 – 3.37 | <0.001 | 1.91 | 1.19 – 3.04 | 0.008* |